spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  anticoagulant therapy 

 HSMN NewsFeed - 12 May 2020
CytoSorb(R) is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
Devices Regulatory
 HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Jun 2018
Roche introduces first self-testing device for Warfarin monitoring with built in Bluetooth(R) technology
Devices Monitoring Product Launch
 HSMN NewsFeed - 30 Oct 2017
FDA Approves New 10 mg Dosing for XARELTO(R) (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jul 2017
Recordati Rare Diseases Introduces New PANHEMATIN(R) (Hemin for Injection) Dosage Strength for Treatment of Acute Intermittent Porphyria (AIP)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 30 Aug 2016
Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4(TM) Study of Factor Xa Inhibitor Antidote AndexXa(TM) (andexanet alfa) in Patients with Acute Major Bleeding
Biopharmaceuticals
 HSMN NewsFeed - 17 Jun 2015
Allergan to Acquire KYTHERA Biopharmaceuticals
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 18 Mar 2015
Selten Pharma, Inc. Receives Orphan Drug Designation From U.S. FDA for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Aug 2014
European Commission Grants Orphan Drug Designation to Soliris(R) (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 May 2014
FDA Approves Conversion of Soliris(R) (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Mar 2014
AngioDynamics Receives Expanded FDA Clearance for AngioVac
Devices Cardiology FDA
 HSMN NewsFeed - 9 Dec 2013
Regado Biosciences Strengthens Executive Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Oct 2013
AngioDynamics Achieves CE Approval for AngioVac
Devices Surgery Cardiology
 HSMN NewsFeed - 13 Sep 2013
Alexion's Soliris(R) (eculizumab) Receives Marketing Approval in Japan for All Patients with aHUS
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jul 2013
Alexion’s Soliris(R) (eculizumab) Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica (NMO)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 8 Oct 2012
AngioDynamics to Acquire Vortex Medical
Devices Mergers & Acquisitions
 HSMN NewsFeed - 26 Aug 2012
Boston Scientific WATCHMAN(R) Left Atrial Appendage Closure Device Receives CE Mark Approval For Expanded Use
Devices Interventional Regulatory
 HSMN NewsFeed - 29 Jun 2012
Actelion Pharmaceuticals Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application for Second Generation VELETRI(R) (epoprostenol) for Injection
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 May 2012
Study of First-in-Class WATCHMAN(R) Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
Devices Interventional Cardiology
 HSMN NewsFeed - 29 Nov 2011
Soliris(R) (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Apr 2011
Alexion Submits Applications for Soliris(R) (Eculizumab) as a Treatment for Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the United States and European Union
Biopharmaceuticals
 HSMN NewsFeed - 1 Dec 2010
Octapharma USA Focuses on Urgent Surgeries as FDA Approves octaplex(R) for Fast Track Development
Biopharmaceuticals Surgery FDA
 HSMN NewsFeed - 1 Jul 2010
FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Apr 2010
Alexion's Soliris(R) (Eculizumab) Receives Marketing Approval in Japan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Aug 2009
Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
Devices Interventional
 HSMN NewsFeed - 17 Aug 2009
Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH)
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2009
Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Devices Interventional FDA
 HSMN NewsFeed - 1 Apr 2009
Alexion Submits NDA in Japan for Soliris(R) (eculizumab) as a Treatment for Patients with PNH
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Mar 2009
Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Mar 2009
Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Sep 2008
Nice Approves Pradaxa(R)*(Dabigatran Etexilate) - First New Oral Anticoagulant in the UK for Over 50 Years
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Mar 2008
MIV Preliminary Nine-Month Human Data Affirms Excellent Safety and Efficacy of VESTAsync(TM) Polymer-Free Drug-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Mar 2008
Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
 HSMN NewsFeed - 13 Dec 2007
PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Dec 2007
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2007
Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2007
Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2007
Inverness Medical Innovations Acquires HemoSense, Inc.
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 25 Sep 2007
Instrumentation Laboratory Receives FDA Clearance for HemosIL RecombiPlasTin 2G Assay
Diagnostics FDA
 HSMN NewsFeed - 2 Sep 2007
New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Aug 2007
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Biopharmaceuticals
 HSMN NewsFeed - 7 Aug 2007
The Medicines Company Submits Angiomax(R) (Bivalirudin) sNDA to Expand Label to Include ACUITY Data
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 Jun 2007
Studies Show Efficacy and Safety of Alexion's Soliris(TM) in Broad Population of PNH Patients
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2007
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 May 2007
FDA Approves FRAGMIN(R) as First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Apr 2007
CHMP Adopts Positive Opinion for Alexion's Soliris(TM) in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Mar 2007
Update: FDA Approves Alexion's Soliris(TM) for All Patients With PNH
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Mar 2007
FDA Approves Alexion's Soliris(TM) for All Patients With PNH
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Nov 2006
The New England Journal of Medicine Publishes Angiomax(R) (Bivalirudin) ACUITY Trial Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Oct 2006
GSK's New Flu Vaccine, FluLaval(TM), Provides Americans With a New Option for Fighting the Flu
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 19

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 19 additional stories matching:
anticoagulant therapy
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.